Barclays analyst Andrew Mok lowered the firm’s price target on Centene (CNC) to $91 from $97 and keeps an Overweight rating on the shares post the Q3 report. While rates appear to be trending in the right direction, 1/1 rates remain the big swing factor in Medicaid margin progression and the company’s 2025 earnings growth, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC: